Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease ; volume:23 ; number:1 ; day:29 ; month:1 ; year:2024 ; pages:1-11 ; date:12.2024
Lipids in health and disease ; 23, Heft 1 (29.1.2024), 1-11, 12.2024
- Creator
-
Huang, Kuiyuan
Huang, Shenan
Xiong, Ming
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12944-024-02026-y
- URN
-
urn:nbn:de:101:1-2024040910203465038553
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Huang, Kuiyuan
- Huang, Shenan
- Xiong, Ming
- SpringerLink (Online service)
Other Objects (12)
Lipid-lowering drugs and inflammatory bowel disease’s risk: a drug-target Mendelian randomization study
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Nicotinic acid: a lipid-lowering agent with unrealized potential
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Lipid-lowering drugs and inflammatory bowel disease’s risk: a drug-target Mendelian randomization study
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Nicotinic acid: a lipid-lowering agent with unrealized potential
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Lipid-lowering drugs and inflammatory bowel disease’s risk: a drug-target Mendelian randomization study
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Nicotinic acid: a lipid-lowering agent with unrealized potential
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany